NVAX · NASDAQ
Novavax (NVAX) Stock Price & Fundamentals
Novavax (NVAX) closed at $622.57 on Oct 9, 2026, down 0.54% from the previous close of $625.96.
Share price, past year
1Y +13.35%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $622.57 |
| Sep 30, 2026 | $645.51 |
| Aug 31, 2026 | $646.86 |
| Jul 31, 2026 | $622.07 |
| Jun 30, 2026 | $625.35 |
| May 29, 2026 | $629.13 |
| Apr 30, 2026 | $611.31 |
| Mar 31, 2026 | $564.31 |
| Feb 27, 2026 | $539.10 |
| Jan 30, 2026 | $558.68 |
| Dec 31, 2025 | $518.17 |
| Nov 28, 2025 | $536.67 |
| Oct 31, 2025 | $547.42 |
Key statistics
- Market cap
- $102.61B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.35
- Revenue (TTM)
- $413.80M
- Net income (TTM)
- −$247.73M
- Shares outstanding
- 164.8M
- Dividend yield
- —
- 52-week range
- $511.36 – $663.75
Novavax's market cap is $102.61B, based on a share price of $622.57 and 164.8M shares outstanding as of Jun 30, 2026.
Financials
Novavax reported revenue of $1.12B for fiscal 2025, up 64.69% from fiscal 2024.
Novavax earned net income of $440.30M in fiscal 2025, a net margin of 39.2%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.12B | +64.7% | $440.30M | 39.2% | $2.58 | — |
| FY2024ended Dec 31, 2024 | $682.16M | −30.7% | −$187.50M | −27.5% | −$1.23 | — |
| FY2023ended Dec 31, 2023 | $983.71M | −50.4% | −$545.06M | −55.4% | −$5.41 | — |
| FY2022ended Dec 31, 2022 | $1.98B | +72.9% | −$657.94M | −33.2% | −$8.42 | — |
| FY2021ended Dec 31, 2021 | $1.15B | +141.0% | −$1.74B | −152.1% | −$23.44 | — |
| FY2020ended Dec 31, 2020 | $475.60M | +2,448.5% | −$418.26M | −87.9% | −$7.27 | — |
| FY2019ended Dec 31, 2019 | $18.66M | −45.6% | −$132.69M | −711.0% | −$5.51 | — |
| FY2018ended Dec 31, 2018 | $34.29M | +10.0% | −$184.75M | −538.8% | −$9.99 | — |
| FY2017ended Dec 31, 2017 | $31.18M | +103.1% | −$183.77M | −589.5% | −$12.56 | — |
| FY2016ended Dec 31, 2016 | $15.35M | — | −$279.97M | −1,823.5% | −$1.03 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $56.70M | −$53.39M | −$0.32 |
| Q1 FY2026ended Mar 31, 2026 | $139.51M | −$9.49M | −$0.06 |
| Q4 FY2025ended Dec 31, 2025 | $147.14M | $17.53M | $0.28 |
| Q3 FY2025ended Sep 30, 2025 | $70.45M | −$202.38M | −$1.25 |
| Q2 FY2025ended Jun 30, 2025 | $239.24M | $106.51M | $0.62 |
| Q1 FY2025ended Mar 31, 2025 | $666.66M | $518.65M | $2.93 |
| Q4 FY2024ended Dec 31, 2024 | $88.31M | −$81.03M | −$0.41 |
| Q3 FY2024ended Sep 30, 2024 | $84.51M | −$121.30M | −$0.76 |
Company profile
- Name
- Novavax, Inc.
- Ticker
- NVAX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 21 Firstfield Rd, Gaithersburg, MD
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001000694
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 23, 2026
- May 6, 2026
- May 6, 2026
- Feb 26, 2026
- Feb 26, 2026
- Jan 20, 2026
Frequently asked questions
What is Novavax's stock price?
Novavax (NVAX) closed at $622.57 on Oct 9, 2026, down 0.54% from the previous close of $625.96.
What is Novavax's market cap?
Novavax's market cap is $102.61B, based on a share price of $622.57 and 164.8M shares outstanding as of Jun 30, 2026.
How much revenue does Novavax make?
Novavax reported revenue of $1.12B for fiscal 2025, up 64.69% from fiscal 2024.
Does Novavax pay a dividend?
Novavax's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Novavax, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures